Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD4+ T cells specific for Ambrosia elatior (common ragweed) allergen-derived peptides are a specialized population of helper T lymphocytes that orchestrate the allergic immune response to ragweed pollen. These cells recognize specific peptide epitopes, primarily derived from the major allergen Amb a 1, when presented by MHC class II molecules on the surface of antigen-presenting cells [Ndhlovu et al., 2012]. In sensitized individuals, these T cells predominantly adopt a Th2 phenotype, secreting pro-inflammatory cytokines such as IL-4, IL-5, and IL-13 that drive the production of allergen-specific IgE and the recruitment of eosinophils, leading to the clinical symptoms of allergic rhinitis and asthma [Wopfner et al., 2005]. As a therapeutic target, these cells are modulated through allergen-specific immunotherapy (AIT) to restore immune tolerance. AIT works by inducing a state of peripheral T-cell tolerance through mechanisms such as T-cell anergy, deletion, or the induction of regulatory T cells (Tregs) that suppress allergic inflammation via the secretion of IL-10 and TGF-beta [Akdis & Akdis, 2014]. Current therapeutic agents targeting these cells include standardized ragweed pollen extracts for sublingual or subcutaneous administration, as well as investigational peptide-based vaccines designed to provide the necessary T-cell stimulus while minimizing the risk of IgE-mediated systemic reactions [Larché, 2007].
Induction of peripheral T-cell tolerance through mechanisms such as T-cell anergy, immune deviation from Th2 to Th1 phenotypes, and the expansion of IL-10-secreting regulatory T cells (Tregs) [Akdis & Akdis, 2014].
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD4+ T cells specific for Ambrosia elatior allergen-derived peptides (Ragweed-specific CD4+ T cells).